SLN COMP 1
Alternative Names: SLN-COMP-1Latest Information Update: 23 Apr 2023
At a glance
- Originator Silence Therapeutics
- Class Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Autoimmune disorders
Most Recent Events
- 29 Mar 2023 SLN COMP 1 is available for licensing as of 29 Mar 2023. https://silence-therapeutics.com/partnering/default.aspx
- 29 Mar 2023 Preclinical trials in Autoimmune disorders in United Kingdom (Parenteral) (Silence Therapeutics pipeline, March 2023)
- 31 Mar 2021 Silence Therapeutics has patent protection for mRNAi GOLD™ platform (Silence Therapeutics website, March 2023)